SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCrysts continued share-price weakness despite growing ORLADEYO sales is fueling frustration with management and its acquisition-led strategy, including concerns about debt, dilution, and HAE competition. Bullish holders point to reported strength in pediatric demand and future Navenibart and Netherton data, while skeptics see those pipeline prospects as uncertain and the stock as persistently undervalued.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep slide to record lows, with traders linking the weakness to concerns about Trumps political prospects ahead of the midterms and the companys limited business traction. Discussion is overwhelmingly bearish, though some traders see a possible short-term bounce.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreed sale of its prenatal testing business to Labcorp is driving the sharp rally, with traders viewing the deal as a balance-sheet and strategic reset. Others argue the unit was a meaningful revenue source and question whether the remaining business can overcome operating and debt concerns.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are under heavy selling pressure, with traders focused on the proposed Monee public listing or spin-off and debating whether it could weaken Seas remaining business or eventually benefit shareholders who receive Monee shares. Some also point to insider selling and a technical breakdown, while others view the separation as potentially positive; the discussion does not establish a single confirmed cause for the selloff.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound is fueling speculation about a potential buyout, with traders reading the CEOs 15th-anniversary message and conference plans as possible signals. The discussion also centers on the Phase 3 REGAL trials pending 80-event trigger and SLS009 data, though no deal or new trial result is confirmed, and skeptics emphasize the binary clinical risk.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs strong third-quarter earnings beat and raised 2026 outlook have been overshadowed by a sharp share-price decline, with traders debating whether robust orders and services demand can outweigh weaker free cash flow, cost pressures, and an insurance-business loss. Some view the selloff as an overreaction to solid results, while others question margins and cash conversion.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following segments: Walmart U.S., Walmart International, and Sam's Club U.S. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club U.S. segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmarts rally is drawing attention amid a defensive rotation out of technology and into consumer staples, with traders also citing Deutsche Banks upgrade to Buy. Bulls point to the stocks momentum and value-focused consumer demand, while skeptics argue its elevated valuation could make the safe-haven trade vulnerable if technology stocks rebound.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after a quarterly earnings beat and raised full-year outlook, alongside record backlog and strong missile demand. Traders praised the results but debated the muted, negative share-price reaction, with some expecting a stronger rally.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat was overshadowed by a narrowed full-year profit outlook with an unchanged midpoint, prompting a sharp selloff despite a higher free-cash-flow outlook and a new share-buyback authorization. Traders are split between viewing the drop as a buying opportunity given cash generation and buybacks, and seeing the guidance as a sign of weaker prospects.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans quarterly results, raised 2026 earnings outlook and record backlog are driving attention, with traders highlighting strong defense demand and the earnings-related share gain. The reaction is broadly bullish, though some remain cautious about whether the move can hold after the stocks prior weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug

Equity

Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 14.04% on an annualized basis producing an average annual return of 27.55%. Currently, Ascendis Pharma has a market capitalization ofread more...

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.08% on an annualized basis producing an average annual return of 29.64%. Currently, Ascendis Pharma has a market capitalization ofread more...

Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock

Mads Bodenhoff, SVP & PAO at Ascendis Pharma (NASDAQ:ASND), reported an insider sell on September 9, according to a new SEC filing.
What Happened: Bodenhoff's decision to sell 3,000 shares of Ascendis Pharmaread more...

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged

BioMarin and Ascendis settled a global patent dispute over the achondroplasia drug Yuviwel on Sunday. 

Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday.

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)read more...

FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo

BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.

• Reported GAAP EPS of $3.22 up 603.12% YoY
• Reported revenue of $339.29M up 114.68% YoY

Ascendis Pharma faces material risks from regulatory review timelines for YUVIWEL, potential reimbursement and pricing challenges for its product portfolio, and dependencies on third-party manufacturing and logistics for commercial operations.

Ascendis Pharma delivered strong 105% year-over-year product revenue growth in Q2 2026 and achieved profitability, supported by robust demand for its TransCon commercial products and continued advancement of its clinical pipeline.

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

Neutral Sentiment

<ul class="summary-bullets"><li>Final European Commission authorization is still pending, with a decision expected in the fourth quarter of 2026 and a potential first launch in Germany in the first quarter of 2027.</li><li>Ascendis has three approved commercial products.</li><li>TransCon CNP, marketed as YUVIWEL in the U.S., received FDA approval in February 2026.</li></ul>Ascendis Pharma (ASND) said on Friday that it has received a positive European regulatory opinion for its once-weekly treatment for children with achondroplasia.Shares of the company closed down 0.6%, as investors likely viewed the positive opinion as expected, provided it is already approved in the U.S. TransCon CNP, marketed as YUVIWEL in the U.S., received FDA approval in February 2026 to increase linear growth in children two years and older with open growth plates.<h2 class="st-heading-2">CHMP Opinion On Ascendis Drug</h2>Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia for children two years of age and older whose epiphyses, or the expanded end of a long bone, are not closed. The opinion followed review of data from three randomized, double-blind, placebo-controlled trials plus up to three years of open-label extension results, including the pivotal ApproaCH trial. Final European Commission authorization is still pending, with a decision expected in the fourth quarter of 2026 and a potential first launch in Germany in the first quarter of 2027.Chief Executive Officer Jan Mikkelsen said the positive opinion reflects the unique profile of TransCon CNP and that the therapy remains a foundational product in the company’s growth disorder portfolio supporting its longer-term objectives.Ascendis has three approved commercial products, including TransCon CNP. In the second quarter, or its first quarter of commercial sales, the drug recorded €7.6–8 million in revenue, accounting for a small portion of the company’s overall product revenue of €315 million. YORVIPATH accounts for a lion’s share of the company’s overall sales.<h2 class="st-heading-2">How Did ASND Retail Traders React?</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/ASND">ASND stock</a>&nbsp;stayed within bearish territory over the past 24 hours, while message volume stayed within normal levels.ASND stock has gained 6% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omeros-shares-slide-after-chmp-upholds-negative-opinion-on-drug-analyst-sees-buying-opportunity-at-16/cZxKQ9ERBtG">Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ascendis Pharma logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Ascendis Pharma

iShares Biotechnology ETF

T Rowe Price Capital Appreciation Equity ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$233.28
Prev Close	$229.95
Open	$231.00
Dividend Yield	N/A
50-Day Moving Average	$243.64
Beta	0.52
Avg. Volume	893,313.42
PE Ratio	16.58

52-Week High	$282.15
52-Week Low	$188.07
Market Capitalization	$14.34B
EPS (Annual)	-$4.25
Price to Book	9.20
Revenue Per Employee	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

ASND Fundamentals